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Abstract
Gastric neuroendocrine tumors (NETs) are rare and can occur in patients with chronic atrophic gastritis (type I), multiple
endocrine neoplasia 1 syndrome, or Zollinger–Ellison syndrome (type II), or sporadically (type III). Types I and II gastric
NETs usually present as multiple small sessile lesions and are usually found coincidentally. Type III lesions are usually
larger, isolated, and responsible for iron deﬁciency anemia and abdominal pain. This article is part of an expert
encyclopedia.
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Video Related to this Article
Technique
• Esophagogastroduodenoscopy.
Material
• Endoscope: EG-201FP; Fujinon, Saitama, Japan.
Background and Endoscopic Procedures
Neuroendocrine tumors (NETs) are rare tumors that most
likely arise from progenitor cells and develop neuroendocrine
characteristics.1 NETs can be located in the lungs (approxi-
mately 20%) and very rarely in the breast, ovary, and prostate,
but the majority can be found in the gastrointestinal tract.2
Gastroenteropancreatic NETs usually do not produce peptides
or hormones. Approximately 25% of all NETs arise in the
small intestine. Other prevalent sites are the colorectum (15%
of all NETs) and the pancreas (7%).
Gastric NETs account for approximately 5% of all NETs
and are often diagnosed coincidentally during upper en-
doscopy for unrelated complaints. Gastric NETs can be div-
ided into three types.1
Type I tumors account for approximately 80% of all gastric
NETs and are associated with achlorhydria and hypergas-
trinemia, which are present in patients with chronic atrophic
gastritis.3 The elevated levels of gastrine stimulates the growth
of enterochromafﬁn-like cells. This results in dysplasia
that may lead to NET. The estimated incidence of gastric NET
is between 1% and 12.5%.3 The annual incidence of NET
in patients with chronic atrophic gastritis is estimated to be
0.4%.4 Type I gastric NETs usually present as multiple small
(2–10 mm) sessile lesions.5 In approximately 20%, macro-
scopic lesions are absent and the NETs are found diagnosed in
biopsy specimens.5 These tumors are usually well differen-
tiated and with low Ki67. Invasion of the muscular layer
by metastasis is extremely rare and only occurs in lesions
41 cm. Therefore, for small type I gastric NETs annual
endoscopic surveillance is advised.1,5 In case of lesions
41 cm, endoscopic ultrasound should be performed to assess
wall and lymph nodal invasion before polypectomy by snare
or endoscopic mucosal resection.5
Type II gastric NETs are associated with multiple endocrine
neoplasia (MEN) type I syndrome and to a lesser extent with
Zollinger–Ellison syndrome. They account for 5–6% of gastric
NETs.5 Morphologically, they are similar to type I lesions and are
usuallyo1–2 cm. In contrast to type I lesions, inﬁltrative growth
and metastatic spread is more prevalent (10–30%). For these le-
sions local excision (endoscopic or surgical) is generally advised.5
Type III tumors are sporadic tumors and account for 15–25%
of all gastric NETs. In contrast to type I and type II tumors, type
III tumors are usually solitary and 42 cm. They are usually
diagnosed during upper endoscopy performed for the evaluation
of iron deﬁciency anemia or abdominal pain. Invasive growth
and metastatic spread are far more common, occurring in
50–100% of cases. Mortality is approximately 50%.5 Therapy is
similar to therapy for gastric adenocarcinoma and includes par-
tial or total gastrectomy with lymph node dissection.5
Key Learning Points/Tips and Tricks
• Gastric NETs can be associated with chronic atrophic
gastritis (type I), MEN-1 syndrome or Zollinger–Ellison
syndrome (type II), or can occur sporadically (type III).
• Prognosis for type I and type II lesions is good.
This article is part of an expert video encyclopedia. Click here for the full
Table of Contents.
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• Type III lesions often invade the muscular layer and often
metastasize, and should therefore be treated as gastric
adenocarcinoma.
Scripted Voiceover
Time (min:sec) Voiceover text
00:00–00:10 This is a video of a gastroscopy in a 64-year-old
female with a longstanding history of chronic
atrophic gastritis.
00:15–00:30 She has no abdominal symptoms. The
investigation is being performed because during
a previous upper endoscopy, small nodular
lesions were detected in the gastric body, which
proved to be gastric neuroendocrine tumors.
00:33–00:47 In the gastric body multiple 4–6 mm sized round
sessile lesions can be observed. Some of the
lesions have discrete ulceration on their tops.
00:51–01:08 Because of the usually benign course of lesions
that are smaller than 1 cm, no resections are
performed. Instead, annual gastroscopy is
performed, to monitor these lesions. If growth is
observed, most lesions can be resected
endoscopically.
01:13–01:34 In this 56-year-old female with multiple endocrine
neoplasia (MEN)-1 syndrome, two 4–6 mm
small sessile lesions proved to be
neuroendocrine tumors (NET) as well. In
general, it is recommended to resect these type
II gastric NETs.
References
1. Ramage, J. K.; Ahmed, A.; Ardill, J.; et al. UK and Ireland Neuroendocrine
Tumour Society. Guidelines for the Management of Gastroenteropancreatic
Neuroendocrine (Including Carcinoid) Tumours (NETs). Gut 2012, 61, 6–32.
2. Hemminki, K.; Li, X. Incidence Trends and Risk Factors of Carcinoid Tumors: A
Nationwide Epidemiologic Study from Sweden. Cancer 2001, 92, 2204–2210.
3. Vannella, L.; Lahner, E.; Annibale, B. Risk for Gastric Neoplasias in Patients
with Chronic Atrophic Gastritis: A Critical Reappraisal. World J. Gastroenterol.
2012, 18, 1279–1285.
4. Vannella, L.; Sbrozzi-Vanni, A.; Lahner, E.; et al. Development of Type I Gastric
Carcinoid in Patients with Chronic Atrophic Gastritis. Aliment. Pharmacol. Ther.
2011, 33, 1361–1369.
5. Delle Fave, G.; Kwekkeboom, D. J.; Van Cutsem, E.; et al. Barcelona
Consensus Conference Participants. ENETS Consensus Guidelines for the
Management of Patients with Gastroduodenal Neoplasms. Neuroendocrinology
2012, 95, 74–87.
Gastric Neuroendocrine Tumors177
